Canopy Growth Corp (WEED)

[Wo]

Speculation: not to solicit, or imply. I had earlier presented my hypothesis regarding x biotech company(s) that may be of interest for either partnership or acquisition within Canopy Growth Corporation. A company I thought present excellent value was Delivera Corp. Tsxv: DVA. The company has engineered a proprietary transdermal cream technology to deliver pharmaceutical pain relief medicine. The biotechnology has proven successfully effective with common formulations such as Ibuprofen.

The potential market applications are apparent. A non ingested, topical, direct to affected area pain relief formulation. Patients with compromised digestion, and accute pain are able to target affected areas directly. There is a synergistic potential in medical and hospital settings, long term care and at home treatment. The technology compliments Canopy’s recent partnership announcement with Centric Health, the Clinical research and Trials of Canopy Health and the several other initiatives Canopy Growth is taking towards the medical applications of Cannabis. On top of that, in February 2016, DVA and Canopy had announced a formal agreement to market such types of products once they became available.

With that said, I present the most recent development from DVA:

( you will notice the familiar name to the Cannabis Sector of Canaccord Genuity Corp). Full Disclosure, I am currently Long DVA.

https://finance.yahoo.com/news/delivra-receiving-interest-expertise-technology-110000081.html?.tsrc=applewf

Delivra Receiving Interest for its Expertise and Technology for Use in the Cannabis and Pharma Industries

CNW Group
October 1, 2018, 5:00 AM MDT
TORONTO , Oct. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company's proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries.

As a result of these inquiries, the Company has engaged Canaccord Genuity Corp. to act as exclusive financial advisor to identify, review, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.

Delivra has not set a timetable for completion of the review process and it does not intend to disclose further developments with respect to the review unless and until required by law or until such disclosure is deemed appropriate by the Company. Delivra cautions that there are no guarantees that the process will result in a transaction of any kind, and if a transaction is undertaken, that there is no guarantee as to its terms or timing.